Aggressive NK-cell leukemia

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:86873C94.7
Who is this for?
Show terms as
3Active trials32Specialists8Treatment centers

Where are you in your journey?

ℹ
UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Also known as:

ANKCLAggressive NK-cell lymphomaNK-cell LGL leukemiaNK-cell large granular lymphocyte leukemia
Orphanet ↗NORD ↗

FDA & Trial Timeline

6 events
Dec 2024JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Institute of Hematology & Blood Diseases Hospital, China — PHASE2

TrialRECRUITING
Sep 2023Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia

Hiroshima University Hospital — PHASE1, PHASE2

TrialRECRUITING
May 2023Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia

The Affiliated Hospital of Xuzhou Medical University — PHASE2

TrialRECRUITING
Sep 2022ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

Abcuro, Inc. — PHASE1, PHASE2

TrialACTIVE NOT RECRUITING
Aug 2021A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Memorial Sloan Kettering Cancer Center — PHASE1

TrialRECRUITING
Aug 2013Registry of the German CLL Study Group

German CLL Study Group

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Aggressive NK-cell leukemia.

3 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

3 recruitingView all trials with filters →
Phase 22 trials
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Phase 2
Actively Recruiting
· Sites: Tianjin, Tianjin Municipality; Tianjin · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia
Phase 2
Actively Recruiting
· Sites: Xuzhou, Jiangsu · Age: 18–70 yrs
View on ClinicalTrials.gov ↗I'm interested →

Specialists

Showing 25 of 32View all specialists →
DM
David Maloney
Specialist
PI on 11 active trials
MM
Mitchell Cairo, MD
HAWTHORNE, NY
Specialist
PI on 11 active trials
AM
Alison Moskowitz, MD
FAIRFIELD, CT
Specialist
PI on 6 active trials1 Aggressive NK-cell leukemia publication
WM
Wyndham H Wilson, M.D.
BETHESDA, MD
Specialist
PI on 8 active trials
RN
Ryotaro Nakamura
Duarte, California
Specialist

Rare Disease Specialist

PI on 6 active trials
SM
Steven Horwitz, MD
Specialist
PI on 4 active trials
TM
Thomas E. Witzig, MD
ROCHESTER, MN
Specialist
PI on 9 active trials
EM
Elizabeth Fox, MD
Specialist
PI on 5 active trials
GC
George Chen
Specialist
PI on 2 active trials
NR
Nancy Wells, DNSc, RN
Specialist
PI on 2 active trials
WM
Wan-Jen Hong, MD
STANFORD, CA
Specialist
PI on 1 active trial
YO
Yasuhiro Oki
HOUSTON, TX
Specialist
PI on 1 active trial
WP
Won Seog Kim, MD, PhD
Specialist
PI on 6 active trials
HL
Hongtao Liu
MADISON, WI
Specialist
PI on 4 active trials
TM
Thomas A Waldmann, M.D.
Specialist
PI on 5 active trials
JS
John Sarantopoulos
SAN ANTONIO, TX
Specialist
PI on 1 active trial2 Aggressive NK-cell leukemia publications
PP
Pierluigi Porcu
PHILADELPHIA, PA
Specialist
PI on 2 active trials
BM
Brian Hill, MD
Specialist
PI on 1 active trial
AW
Ann Woolfrey
SEATTLE, WA
Specialist
PI on 5 active trials
HM
Helen Heslop, MD
HOUSTON, TX
Specialist
PI on 6 active trials
TM
Tom R. Fitch, M.D.
GLENDALE, AZ
Specialist
PI on 1 active trial
MS
Mohamed Sorror
SEATTLE, WA
Specialist
PI on 4 active trials1 Aggressive NK-cell leukemia publication
MM
Minoti Hiremath, MD
Specialist
PI on 2 active trials
PM
Paul Armistead, MD
CHAPEL HILL, NC
Specialist
PI on 1 active trial
TP
Tonya M. Peele
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center ↗

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center ↗

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program ↗

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site ↗

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site ↗

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site ↗

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine ↗

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program ↗

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Aggressive NK-cell leukemia.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Aggressive NK-cell leukemiaForum →

No community posts yet. Be the first to share your experience with Aggressive NK-cell leukemia.

Start the conversation →

Latest news about Aggressive NK-cell leukemia

Disease timeline:

New recruiting trial: JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

A new clinical trial is recruiting patients for Aggressive NK-cell leukemia

New recruiting trial: Registry of the German CLL Study Group

A new clinical trial is recruiting patients for Aggressive NK-cell leukemia

New recruiting trial: National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia

A new clinical trial is recruiting patients for Aggressive NK-cell leukemia

New recruiting trial: Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia

A new clinical trial is recruiting patients for Aggressive NK-cell leukemia

New recruiting trial: A Study of Ruxolitinib and Duvelisib in People With Lymphoma

A new clinical trial is recruiting patients for Aggressive NK-cell leukemia

New recruiting trial: PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

A new clinical trial is recruiting patients for Aggressive NK-cell leukemia

New recruiting trial: Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

A new clinical trial is recruiting patients for Aggressive NK-cell leukemia

New recruiting trial: Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia

A new clinical trial is recruiting patients for Aggressive NK-cell leukemia

New recruiting trial: Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia

A new clinical trial is recruiting patients for Aggressive NK-cell leukemia

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Aggressive NK-cell leukemia

Are there clinical trials for Aggressive NK-cell leukemia?

Yes — 3 recruiting clinical trials are currently listed for Aggressive NK-cell leukemia on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Aggressive NK-cell leukemia?

25 specialists and care centers treating Aggressive NK-cell leukemia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.